Core Viewpoint - Huayang Intelligent's large-dose high-viscosity continuous injection device is currently in the functional prototype verification stage, and the company is collaborating with clients on foundational drug delivery research. The commercialization of this product is closely tied to the drug approval process, and since the related drug is still in the early research phase, it will not impact the company's revenue in the short term [1] Group 1 - The large-dose high-viscosity continuous injection device is in the functional prototype verification stage [1] - The company is working with clients on foundational drug delivery research [1] - The commercialization of the product is linked to the drug approval process [1] Group 2 - The related drug is still in the early research phase [1] - The product will not have a short-term impact on the company's revenue [1]

Financial Performance - Revenue in the first three quarters decreased by 14.52%, but net profit attributable to shareholders in Q3 increased by 61.24%, and non-recurring net profit surged by 107.84%. The improvement in profitability is attributed to effective cost and expense management despite declining revenue [1] - Financial expenses increased by 224.45% year-on-year, while sales and management expenses decreased by 35.33% and 21.40%, respectively. The rise in financial expenses is mainly due to interest from structured deposits, while the decrease in sales and management expenses is due to reduced advertising costs and lower operational expenses [2] Core Business Operations - The micro-special motor and components business accounted for 92.63% of revenue in the first half of the year. However, sales volume and prices have shown a temporary decline due to structural pressure in downstream markets such as home appliances and medical devices [2] - The precision injection drug delivery device business represented 6.36% of revenue in the first half. The development of high-viscosity continuous injection devices is ongoing, currently in the functional prototype verification stage, with commercialization closely tied to the drug approval process [2] - Accounts receivable increased by 24.06% year-on-year, significantly outpacing revenue decline. The increase is attributed to delayed pricing cycles and outstanding payments from clients. The company has implemented measures to enhance credit management and payment assessment mechanisms [3] Research and Development - The focus for 2025 is on the core technology of frameless motors, with ongoing development and market application assessments. Product mass production has not yet been achieved [3] - R&D expenses decreased by 15.43% year-on-year, primarily due to management optimization and efficiency improvements. This reduction will not impact the progress of key projects such as frameless motors and high-viscosity injection devices [3]

Core Insights - The 2025 14th Annual Conference on the Development of Listed Companies and the Hainan Free Trade Port Opportunities Exchange Conference will be held in Haikou, Hainan from December 11 to 13, 2025, focusing on the development opportunities for listed companies [1] - Wu Wenjing, the Secretary of the Board of Jiangsu Huayang Intelligent Equipment Co., Ltd. (stock code: 301502), was awarded the title of "2025 Best Secretary of the Board of the Growth Enterprise Market," highlighting the company's governance level and development potential [1][3] Company Overview - Huayang Intelligent is committed to the core values of "Quality Achieves Development, Innovation Creates the Future" and aims for a strategic goal of "Centennial Huayang, 10 Billion Market Value," steadily progressing in the precision motor and medical device sectors [3] - The company has established three production bases and four wholly-owned subsidiaries, holding qualifications such as two national high-tech enterprises and one provincial enterprise technology center, which solidify its foundation for high-quality development [3] Business Performance - In the motor industry, Huayang Intelligent serves leading home appliance companies like Midea, Gree, Haier, Hisense, and Aux, becoming a core supplier due to its strong technology and product quality [4] - The medical device segment has successfully developed precision drug delivery devices such as electronic injection pens and micro-infusion pumps, which are used for various medications, and has established long-term partnerships with well-known pharmaceutical companies [4] - The company successfully went public on the Shenzhen Stock Exchange's Growth Enterprise Market on February 2, 2024, marking a new chapter in its capitalized development [4] Future Outlook - Wu Wenjing's recognition is seen as a milestone in her career and reflects Huayang Intelligent's emphasis on standardized operations and investor relations management [4] - The company plans to leverage this recognition to further develop micro-special motors and transmission technologies, expand into smart home and smart medical applications, and enhance innovation in drug delivery devices to deliver better performance for investors and society [4]

Group 1 - The core viewpoint of the article is that Huayang Intelligent is actively developing its frameless motor project, which has applications in robotics, collaborative robots, and high-end medical devices [2] - The company is monitoring market applications and customer demands related to its frameless motor technology and will provide updates in future reports and announcements [2] - Currently, Huayang Intelligent's collaboration with Midea Group is limited to white goods-related motor products, and the company has not yet entered the robotics supply chain [2] Group 2 - The company has not initiated the development of hollow cup motors and has not acquired any chip enterprises [2] - Relevant information will be disclosed through the company's announcements in designated media [2]

Group 1 - The company, Huayang Intelligent, responded to investor inquiries regarding the number of shareholders, referring to previous replies for information [2]

Core Viewpoint - Bohai Chemical is planning to sell 100% equity of Tianjin Bohai Petrochemical Co., Ltd. and acquire control of Anhui Taida New Materials Co., Ltd. through a combination of issuing shares and cash payment, which is expected to constitute a major asset restructuring according to regulations [1] Group 1 - The transaction will not lead to a change in the actual controller of the company and does not constitute a restructuring listing [1] - The company has applied for a trading suspension, which will start on December 8, 2025, and is expected to last no more than 10 trading days [1]

Core Viewpoint - Huayang Intelligent (301502.SZ) is steadily advancing its frameless motor project as planned, and it has not yet been applied to humanoid robots [1] Group 1 - The company is currently focused on the development of its frameless motor project [1] - The project is progressing according to schedule [1] - There is no current application of the frameless motor in humanoid robots [1]

Core Viewpoint - Huayang Intelligent (301502.SZ) is steadily advancing its frameless motor project as planned, and it has not yet been applied to humanoid robots [1] Group 1 - The company is making progress on its frameless motor project [1] - The project is currently on schedule [1] - There is no current application of the technology in humanoid robots [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 江苏华阳智能装备股份有限公司（以下简称"公司"）于2025年4月18日召开了第三届董事会第三次会 议、第三届监事会第三次会议，并于2025年5月16日召开2024年年度股东大会，审议通过了《关于续聘 公司2025年度审计机构的议案》，同意续聘中汇会计师事务所（特殊普通合伙）（以下简称"中汇会计 师事务所"）担任公司2025年度财务审计机构。具体内容详见公司于2025年4月21日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于续聘公司2025年度审计机构的公告》（公告编号：2025-021）。 近日，公司收到中汇会计师事务所出具的《关于变更签字注册会计师的告知函》现将具体情况公告如 下： 一、签字注册会计师变更情况 2、诚信记录和独立性 秦聪近三年不存在因执业行为受到刑事处罚，受到证监会及其派出机构、行业主管部门的行政处罚、监 督管理措施，受到证券交易所、行业协会等自律组织的自律监管措施、纪律处分的情况，亦不存在可能 影响独立性的情形。 三、本次变更 ...

证券代码：301502 证券简称：华阳智能 公告编号：2025-053 秦聪，2019年成为中国注册会计师，自2019年开始在中汇会计师事务所执业 并从事上市公司审计，近三年负责并签字的上市公司审计报告合计4家，具备相 应专业胜任能力。 2、诚信记录和独立性 近日，公司收到中汇会计师事务所出具的《关于变更签字注册会计师的告知 函》现将具体情况公告如下： 一、签字注册会计师变更情况 中汇会计师事务所作为公司2025年度财务及内控审计机构，原委派曹建军为 项目合伙人、黄林为签字注册会计师为公司提供2025年度审计服务。因原签字注 册会计师黄林离职，现委派秦聪接替黄林作为签字注册会计师。变更后的项目合 伙人、签字注册会计师分别为曹建军和秦聪。 二、本次变更签字注册会计师基本情况 1、基本信息 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 江苏华阳智能装备股份有限公司（以下简称"公司"）于2025年4月18日召 开了第三届董事会第三次会议、第三届监事会第三次会议，并于2025年5月16日 召开2024年年度股东大会，审议通过了《关于续聘公司2025年度审计机构的议案 ...